Burmeister-Getz, Elise, Niglis, Severine, Papadimitriou, Athanasia, Statelova, Marina, Ren, Xiaojun, Nakhla, Keroles, Sharaby, Sherif, Tariq, Muzammil, Garbuio, Luca and Bakhsh, Sumerah (2025) Predicting and Confirming Bioequivalence of Alpelisib Oral Granules and Tablets for Patients With PIK3CA-Related Disorders. AAPS PharmSciTech, 26 (5). pp. 121-135. ISSN 1530-9932

Abstract

Alpelisib, an oral α-specific phosphoinositide 3-kinase (PI3K) inhibitor, has been shown to be safe and effective for some patients with gain-of-function mutation in the PIK3CA oncogene. Alpelisib has received US FDA accelerated approval as Vijoice® film-coated tablets to treat severe PIK3CA-Related Overgrowth Spectrum (PROS). PROS typically displays clinical manifestations in the first year of patient life. Therefore, oral granules were developed as an age-appropriate pediatric dosage form. Bioequivalence between alpelisib granules and tablet and the effect of food on granules pharmacokinetics were assessed in a single-center, randomized, three-treatment, six-sequence, three-period, crossover study among 60 healthy adults. Participants were randomly assigned to receive a single 50-mg alpelisib dose as: (i) tablet following a meal, (ii) granules following a meal, and (iii) granules while fasting. Statistical analysis of non-compartmental pharmacokinetic parameters demonstrated bioequivalence between the 50-mg alpelisib granules and tablet forms when administered with food: estimated geometric mean ratios (90% confidence interval) for granules-versus-tablet area under the curve (AUC) from time zero to infinity (AUCinf), to the last measurable concentration (AUClast) and maximum observed concentration (Cmax) were 0.984 (0.952, 1.02), 0.980 (0.946, 1.02), and 0.947 (0.891, 1.01), respectively. No clinically relevant food effect on 50-mg alpelisib granules pharmacokinetics was observed. These results were accurately predicted using physiologically based biopharmaceutical modeling. Alpelisib granules provide a bioequivalent alternative to tablets for patients prescribed a 50-mg dose and have difficulty swallowing tablets, an important consideration for convenience and compliance of this standard-of-care chronic therapy for patients with PROS. This study was registered in ClinicalTrials.gov on January 4, 2022 (NCT05195892).

Item Type:	Article
Keywords:	Humans Therapeutic Equivalency Tablets Male Cross-Over Studies Administration, Oral Female Adult Class I Phosphatidylinositol 3-Kinases Young Adult Thiazoles Area Under Curve Middle Aged Food-Drug Interactions Adolescent
Date Deposited:	15 May 2025 00:45
Last Modified:	15 May 2025 00:45
URI:	https://oak.novartis.com/id/eprint/56796